Where are they going? From earlier this year it was announced where Garnier was going, along with other top executives from companies such as Sony.
"JP Garnier, outgoing chief executive of GlaxoSmithKline, has agreed to join a newly formed advisory board of Dubai International Capital, the Middle East Emirate's $13bn sovereign wealth fund. Mr Garnier, who will take up the position in January, will help DIC to seek out investments abroad."
Biotech investments on the rise at Glaxo as well. There's also the newly created Glaxo Venture Fund. We are probably all aware now of the fact that venture capitalists investments are finding their way in to the global market, even with larger healthcare hospitals and facilities as that has been a source for years for funding.
There may be some very lucrative opportunities within, but I assume we will all find out in time, and at this point maybe just good old retirement might be looking pretty good. BD
A $5 million retention bonus apparently wasn't enough to keep Chris Viehbacher (photo) at GlaxoSmithKline. One of the three top GSK execs in the race to succeed Jean-Pierre Garnier as CEO, Viehbacher was passed over in favor of Andrew Witty (photo), who took over officially after the company's annual meeting this spring.
"
0 comments :
Post a Comment